Canada Proposes Amendments to Adverse Drug Reaction Reporting

October 2009

Teresa A. Reguly

Tags:

Advertising and Marketing Food and Drug Regulatory Intellectual Property Life Sciences Pharmaceuticals

Related Expertise

Related Insights

Video: Navigating (and challenging) a changing life sciences regulatory environment
COVID-19 triggers Canadian intellectual property deadline extensions until August 31, 2020
Drug pricing and reimbursement: Canada
Indirect comparisons to an innovative drug’s data can trigger data protection provisions
Health Canada instructed to reconsider scope of CSP protection for drug containing multiple active ingredients

Back